A Case of Fournier's Gangrene Following the Initiation of Dapagliflozin

Since being approved by the United States Food and Drug Administration (FDA) in 2013, sodium-glucose cotransporter-2 inhibitors (SGLT2is) have emerged as an appealing therapeutic choice for patients with diabetes due to their favorable effects on renal and cardiac health. Recent trials have further...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2024-06, Vol.16 (6), p.e63168
Main Authors: Shaykh, Natalie, Agrawal, Avni, O'Brien, Melville C, Rai, Oshin, Tripathi, Vanshika, Jaikaransingh, Vishal
Format: Article
Language:English
Subjects:
Abdomen
Acidosis
Antibiotics
Antidiabetics
Bacteria
Cardiovascular disease
Case reports
Coronary vessels
Creatinine
Diabetes
Ejection fraction
Emergency medical care
Gangrene
Glucose
Heart failure
Hemoglobin
Hygiene
Kidneys
Kinases
Medical imaging
Metabolism
Mortality
Staphylococcus infections
Thrombosis
Trauma
Urinalysis
Urogenital system
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since being approved by the United States Food and Drug Administration (FDA) in 2013, sodium-glucose cotransporter-2 inhibitors (SGLT2is) have emerged as an appealing therapeutic choice for patients with diabetes due to their favorable effects on renal and cardiac health. Recent trials have further expanded the application of these drugs by showing a decrease in mortality rates among patients with both reduced and preserved ejection fraction heart failure, even in those without diabetes. Common adverse effects of SGLT2is include increased urinary frequency and urinary tract infections stemming from elevated glycosuria. Here, we present a case report involving a 66-year-old man who developed Fournier's gangrene (FG) shortly after initiating dapagliflozin - a rare but dangerous adverse effect associated with this medication.
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.63168